Transcriptomics

Dataset Information

0

Putting the STING back into BH3-mimetic drugs for TP53 mutant blood cancers


ABSTRACT: TP53-mutant blood cancers remain a major clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins to promote cancer cell apoptosis. Despite acting downstream of TP53, functional TP53 is required for maximal cancer cell killing by BH3-mimetics through an unknown mechanism. Here, we report TP53 can be activated following BH3-mimetic induced mitochondrial outer membrane permeabilization, which leads to induction of BH3-only proteins, thereby potentiating the pro-apoptotic signal. TP53-deficient lymphomas lack this feed-forward loop, providing opportunities for survival and disease relapse after BH3-mimetic treatment. The therapeutic barrier imposed by defects in TP53 could be overcome by direct activation of the cGAS/STING pathway, which promotes apoptosis of blood cancer cells through TP53-independent BH3-only protein upregulation. Combining clinically relevant STING agonists with BH3-mimetics efficiently killed TP53-mutant mouse B lymphoma, human NK/T lymphoma and acute myeloid leukemia cells. This represents a promising therapy regime that can be fast-tracked to tackle TP53-mutant blood cancers in the clinic.

ORGANISM(S): Mus musculus

PROVIDER: GSE261373 | GEO | 2024/04/25

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA1086799 | ENA
2022-09-25 | PXD030246 | Pride
2023-07-10 | GSE182401 | GEO
2021-12-31 | E-MTAB-10903 | biostudies-arrayexpress
2024-04-04 | GSE245162 | GEO
2024-04-04 | GSE245049 | GEO
2019-11-21 | GSE140489 | GEO
2017-01-26 | GSE86839 | GEO
2016-12-15 | GSE79955 | GEO
| PRJNA756171 | ENA